- Home
- XENE vs CNTA Comparison
XENE vs CNTA Comparison
Compare XENE & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- CNTA
- Stock Information
- Founded
- XENE 1996
- CNTA 2020
- Country
- XENE Canada
- CNTA United Kingdom
- Employees
- XENE N/A
- CNTA N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- CNTA Health Care
- Exchange
- XENE Nasdaq
- CNTA Nasdaq
- Market Cap
- XENE 2.9B
- CNTA 2.3B
- IPO Year
- XENE 2014
- CNTA 2021
- Fundamental
- Price
- XENE $39.04
- CNTA $20.14
- Analyst Decision
- XENE Strong Buy
- CNTA Strong Buy
- Analyst Count
- XENE 10
- CNTA 9
- Target Price
- XENE $52.90
- CNTA $31.75
- AVG Volume (30 Days)
- XENE 795.3K
- CNTA 859.3K
- Earning Date
- XENE 11-03-2025
- CNTA 11-12-2025
- Dividend Yield
- XENE N/A
- CNTA N/A
- EPS Growth
- XENE N/A
- CNTA N/A
- EPS
- XENE N/A
- CNTA N/A
- Revenue
- XENE $7,500,000.00
- CNTA $15,000,000.00
- Revenue This Year
- XENE N/A
- CNTA N/A
- Revenue Next Year
- XENE $207.88
- CNTA N/A
- P/E Ratio
- XENE N/A
- CNTA N/A
- Revenue Growth
- XENE N/A
- CNTA 118.88
- 52 Week Low
- XENE $26.74
- CNTA $9.60
- 52 Week High
- XENE $46.00
- CNTA $25.42
- Technical
- Relative Strength Index (RSI)
- XENE 41.74
- CNTA 34.27
- Support Level
- XENE $37.63
- CNTA $23.45
- Resistance Level
- XENE $42.96
- CNTA $25.35
- Average True Range (ATR)
- XENE 1.60
- CNTA 1.23
- MACD
- XENE -0.47
- CNTA -0.33
- Stochastic Oscillator
- XENE 21.42
- CNTA 37.17
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.